 MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market MNOV and the JASDAQ Market of the Tokyo Stock Exchange Code Number: 4875, today announced that it has received a Notice of Intention to Grant from the European Patent Office for a pending patent application which covers MN-001 tipelukast and MN-002 a major metabolite of MN-001 for the treatment of hypertriglyceridemia, hypercholesterolemia, and hyperlipoproteinemia. Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than July 2034. The allowed claims cover a method of reducing a triglyceride blood level, a method of reducing a total cholesterol blood level, and a method of reducing a low-density lipoprotein LDL blood level using MN-001 or MN-002. 